

# Information Exchange and Data Transformation (INFORMED) Initiative

and the Role of Real World Evidence in Regulatory Science

Sean Khozin, MD, MPH

Senior Medical Officer

Office of Hematology and Oncology Products

Food and Drug Administration

Disclosures: None





# The data deluge

AND HOW TO HANDLE IT: A 14-PAGE SPECIAL REPORT







10 Rules for Managing Global Innovation

What Ever Happened To Accountability?





Government **Executive** 

Five Ways Women Get Ahead

Government **Ever Really** 

Change?

MARCH/APRIL 2013

Does



# THE CONTROL

Using Data to Feed the World, Solve Cold Cases, Battle Malware, Predict Our Fate six

### OFFICER ALGORITHM

Can a Crime Be Preventer Before It Begins? <=

### **NEW WAYS** OF SEEING

Extraordinary Infographics on


### SPECIAL ISSUE

HOW INFORMATION IS DRIVING THE FUTURE

**PLUS** luan Enriquez eprograms Life

lames Gleick Inspirts the Bit






### Big data pipeline in biomedicine




### **Growth of DNA Sequencing**




### **Large amount of diversity**











# **Multiomics**






The expanding universe of big data in the biomedical enterprise







# Must focus on breaking siloes



# Why?



# We are nearing the limits of siloed approaches

### "Driver" mutations in non-small cell lung cancer (NSCLC):

	Adenocarcinoma	Squamous-cell carcinoma
EGFR	5-15%*	<5%†
ALK	5-15%	<5%
HER2	<5%	0 %
BRAF	<5%	0
KRAS	>15%	<5%
PIK3CA	<5%	<5%
AKT1	0	<5%
MAP2K1	<5%	0
MET	<5%	<5%

Pao W, et al. Lancet Oncol. 2011 Feb;12(2):175-80.

	Frequency	
Mutations		
KRAS	32.2%	
EGFR	11.3%	
NF1	8.3%	>
BRAF	7.0%	1
MET exon 14 skipping	4.3%	, O
RIT1	2.2%	
ERBB2	1.7%	
HRAS, NRAS, MAP2K1	1.7%	
Translocations		
ROS1	1.7%	
ALK	1.3%	
RET	0.9%	
Amplifications		
MET	2.2%	
ERBB2	0.9%	

Devarakonda S, et al. Lancet Oncol. 2015 Jul;16(7):e342-51.



# **NSCLC: 2016**

Gene	Alteration	Frequency in NSCLC
AKT1	Mutation	1%
ALK	Rearrangement	3–7%
BRAF	Mutation	1–3%
DDR2	Mutation	~4%
EGFR	Mutation	10–35%
FGFR1	Amplification	20%
HER2	Mutation	2–4%
KRAS	Mutation	15–25%
MEK1	Mutation	1%
MET	Amplification	2–4%
NRAS	Mutation	1%
PIK3CA	Mutation	1–3%
PTEN	Mutation	4–8%
RET	Rearrangement	1%
ROS1	Rearrangement	1%

mycancergenome.org 11



### Siloed data → Big Data → Smart Data

### Reductionist

- One-gene one-drug
- Trials with strict eligibility criteria
- Leap of faith clinical development




### Holistic

- Multiomics
- Pragmatic trials
- Systems biology, predictive analytics

# Information Exchange and Data Transformation (INFORMED)



A holistic approach to oncology regulatory science and big data analytics






# **Uncertainty management**


- Using novel pipelines of high quality data in regulatory decision making can reduce uncertainty
  - RWE
  - Patient reported
  - Biometrics (wearables, implantable, etc)








# **Challenges**More than just technology





# Avoid data standards proliferation


SITUATION: THERE ARE 14 COMPETING STANDARDS.



SITUATION: THERE ARE 15 COMPETING STANDARDS.

# **Big picture: today**







# **Bigger picture: tomorrow**

# The learning health system (IOM)

A system where science, informatics, incentives, and culture are aligned for continuous improvement and innovation

Discovery as a product of the healthcare delivery experience

